International Journal of Immunology is a peer-reviewed open access journal that publishes original research articles as well as review articles in all areas of immunology. Immunology is a diverse and growing discipline that can be defined as the study of the tissues, cells and molecules involved in host defense mechanisms. Immunologists attempt to understand how the immune system develops, how the body defends itself against disease, and what happens when it all goes wrong. Priority is given to work that provides fundamental insight into the workings of the immune system. Areas covered include, but are not limited to, innate immunity and inflammation; development; immune receptors, signaling and apoptosis; antigen presentation; gene regulation and recombination; cellular and systemic immunity; vaccines; immune tolerance; autoimmunity and tumor immunology, microbial immunopathology; and transplantation.

The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in biological sciences. This remarkable growth is stimulated by the influx of investigators from other disciplines such as biochemistry, genetics, molecular biology, microbiology, virology and various medical disciplines. These disciplines are so well interlinked with immunology that no immunological challenge can now be properly addressed without sophisticated applications of expertise of combinations of these disciplines. As a consequence, immunology has become a vast and rich field encompassing discoveries and outlooks that range from the highly clinical to the highly molecular. Although such perspectives may appear diverse, they are, in fact, extremely interdependent. The journal seeks to present a balanced overview of contemporary immunology and melds together different aspects of molecular immunology, immunobiology and clinical immunology.

Immunology is the branch of biomedical science that deals with the response of an organism to antigenic challenge and its recognition of what is self and what is not. It deals with the defense mechanisms including all physical, chemical and biological properties of the organism that help it to combat its susceptibility to foreign organisms, material, etc

Immunology has its origins in the study of how the body protects itself against infectious diseases caused by microorganisms, such as bacteria, viruses, protozoa, and fungi, and also parasitic organisms, such as helminth worms. Research / review articles deals with, among other things, the physiological functioning of the immune system in states of both health and disease; malfunctions of the immune system in immunological disorders (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection); the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.


committee

Members

ThumbnailImage

Giovannino Silvestri

Research Associate

2003-2006 B.S.,       Biology, University of Calabria, Italy.
2006-2009 M.S.,      Biology, University of Calabria, Italy (Magna cum Laude).
2010-2013 Ph.D.,     Molecular and Cellular Biology and Pathology, University of Verona, Italy
                                 Thesis Advisor – Dr. Claudio Sorio.
                                 “Biochemical and functional characterization of the oncosuppressor gene Protein
                                 Tyrosine Phosphatase Receptor Gamma in Chronic Myelogenous Leukemia”.

2009           Best Graduate Award 2009, University of Calabria, Italy, awarded for distinguished      performance in biology.
2010-13     Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy.
2012          14th ESH-iCMLf Travel Award, Baltimore, USA.
2015          Award for Best poster presentation, University of Maryland, USA.
2015          American Society of Hematology Abstract achievement Award winner, Orlando, USA.
2017          September Postdoc Appreciation Month, program in Oncology, University of Maryland,  USA.

Local and National Service
National Service
2017-present Ad Hoc Reviewer, Oncotarget (1), Frontiers in Immunology (1).
Local Service
2018-present Postdoc Peer Mentor Program, University of Maryland, USA.
2018-present Johns Hopkins University and University of Maryland, Baltimore, CTFP
Undergraduate Research Poster Judge

Teaching Service
Undergraduate Student Teaching
2015 Mentor laboratory for The Nathan Schnaper Summer Intern Program (NSIP) in cancer
Research at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA.
2018 Judge, Undergraduate Poster Competition 2018
Stevenson University and Johns Hopkins Medical Institution, Baltimore, USA.
Selected by the Collaborative Teaching Fellows Program to evaluate research posters of
undergraduate students and excite them about research careers.

Major Invited Speeches
National
1. Silvestri, G., MicroRNAs as regulators of stem and progenitor CML cells function, ESHiCMLf,
Philadelphia, 2014.
2. Silvestri, G., Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML, 57th ASH, Orlando, 2015.


International

1. Silvestri, G., The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. ESH-iCMLf, Estoril, Portugal, 2017.

Proffered Communications: oral (O) and poster (P) presentation

1. Morsi H., El Ayoubi H., Moratti E., Vezzalini M., Silvestri G., Stradoni R., Murineddu M., Gabbas A., Monne M. and C. Sorio. High Resistance Rate of Chronic Myeloid Leukaemia (CML) to Imatinib Myselate (IM) Might be related to Protein Tyrosine Phosphatase Receptor Type Gamma (PTPRG) Down-Regulation. Proceedings Qatar Foundation Annual Research Forum Epub: November 2011 (O).
2. Bellisola G., Cinque G., Vezzalini M., Silvestri G., Redaelli S., Gambacorti Passerini C., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier Transform InfraRed microspectroscopy (microFTIR) and unsupervised Hierarchical Cluster Analysis (HCA) Proceeding of the Synchrotron Radiation User Meeting Oxford, UK, September 2012. (P).
3. Silvestri G*., Mirenda M., Vezzalini M., Moratti E., Laudanna C. and C. Sorio. Molecular mechanisms of the antiproliferative effect of Protein Tyrosine Phosphatase Receptor-like Gamma (PTPRG): BCR/ABL and LYN kinase as key targets. Proceeding of the 14th ESHiCMLf International Conference on CML Biology and Therapy. Baltimore, Usa, September 2012 (P) (*): recipient of the iCMLF travel award.
4. Bellisola G., Cinque G., Vezzalini M., Moratti E., Silvestri G., Redaelli S., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy (microFTIR) and unsupervised pattern recognition. Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy. Baltimore, USA, September 2012 (P).
5. Bellisola G., Cinque G., Sandt C., Dumas P., Silvestri G. and C. Sorio. Oncosuppressive effect
of direct transduction of receptor-type tyrosine-protein phosphatase gamma (PTPRG) intracellular catalytic domains in K562 cells. Proceeding of the 15th ESH-iCMLf International Conference on CML Biology and Therapy. Estoril, Portugal, September 2013 (P).
6. Tomasello L., Silvestri G., Della Peruta M., Fiorini Z., Vezzalini M. and Claudio Sorio. Protein
Tyrosine Phosphatase Receptor Type Gamma is an inhibitor of critical BCR/ABL driven pathways in Chronic Myeloid Leukemia. Societa’ Italiana di Cancerologia. Ferrara, Italy, September 2014 (O).
7. Bellisola G., Tomasello L., Fiorini Z., Silvestri G., Vezzalini M. and Claudio Sorio. Direct transduction of Receptor-Type Protein Tyrosine-Phosphatase Gamma (PTPRG) intracellular catalytic domains in K562 cells. Societa’ Italiana di Cancerologia. Ferrara, Italy, September 2014 (P).
8. Silvestri G*., Ellis J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Reid A., Milojkovic D., Apperley J., Baer M., Trotta R., and D. Perrotti. MicroRNAs as regulators of stem and progenitor CML cells function. Peer reviewed and printed in the Proceedings of the 2014 ESH-iCMLf International Conference on CML-Biology and Therapy, Philadelphia (O). (*): Invited Speaker.
9. Silvestri G., Ellis J.J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Roy D-C., Hokland
P., Milojkovic D., Reid A., Apperley J.F., Livak F.M., Baer M.R., Trotta R., and D. Perrotti. miR-300 acts as a tumor suppressor in Ph+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 56th ASH Annual Meeting 2014 (P).
10. Silvestri G*., Justin Ellis, Lorenzo Stramucci, Jason G Harb, Paolo Neviani, Guido Marcucci,
Denis-Claude Roy, Peter Hokland, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M. Livak, Maria R. Baer, Rossana Trotta, and Danilo Perrotti. miR-300 acts as a tumor suppressor in Ph+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. UMB Cancer Center Retreat, Baltimore, USA, May 18, 2015.(P) (*): Best Poster Presentation.
11. Silvestri G*., Stramucci L, Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger MW., Bhatia R., Gambacorti- Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R. and Perrotti D. Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-betacatenin- modulator miR-300 in leukemic stem/progenitor and NK cell proliferation and survival in CML. Peer reviewed and printed in the Proceedings of the 2015 ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal (O). (*): Best scored Biology Abstract.
12. Silvestri G*., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K.,
Machova Polakova K., Roy D-C, Hokland P., Deininger MW., Bhatia R., Gambacorti- Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 57th ASH Annual Meeting 2015 (O). (*): ASH travel award.
13. Trotta R., Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia Page 6 R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Proceeding of the AACR Annual Meeting (New Orleans, LA) 2016 (P).
14. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia R., Gambacorti- Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in the Haematologica (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Copenhagen, Danmark. 2016. (O).
15. Yu J.E., Silvestri G., Stramucci L., Livak F.M., Baer M.R., Trotta R., and Perrotti, D. The Role of SETBP1 in Leukemia-Initiating Cell Survival and Self-Renewal in Adult Ph+ B-ALL. ESH-iCMLF ESH-iCMLf International Conference on CML-Biology and Therapy, Houston TX Sept. 2016 (O).
16. Yu J.E., Silvestri G., Stramucci L., Sanada M., Yamaguchi T., Du Y., Westermarck J., Caligiuri M.A., Garzon R., Milojkovic D., Apperley J.F., Roy D-C., Marcucci G., Calabretta, B., Baer M.R., Trotta R. and Perrotti D. Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 –Mediated Suppression of PP2A Activity Peer Reviewed and Published in Blood (Suppl.) dedicated to the 58th ASH Annual Meeting 2016 (P).
17. P. Burda, N. Čuřík, K. Šrůtová, F. Savvulidi, G. Silvestri, H. Klamová, P. Pecherková, Ž. Sovová, J. Koblihová, T. Stopka, D. Perrotti, K. Machová Poláková Myc-dependent repression mechanism of the mir-150 transcriptional regulation in chronic myeloid leukemia. Peer Reviewed and Published in the Leukemia (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Madrid, Spain. 2017 (P).
18. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. UMB CCC Retreat, September 2017 (P).
19. Silvestri G*., Stramucci L., Ellis J., Yu J., Harb JG, Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., , Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal Oct. 2017 (O). (*): selected for Key note lecture.
20. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell- Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 59th ASH Annual Meeting 2017 (O).
21. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. Proceeding of the AACR Annual Meeting, Chicago, 2018 (P).
22. Trotta R., Silvestri G., Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. Proceeding of the AACR Annual Meeting Chicago, 2018 (P).

Peer-reviewed journal articles

1. Bellisola G., Cinque G., Vezzalini M., Moratti E., Silvestri G., Redealli S., Gambacorti
Passerini C., Wehbe K., and C. Sorio. Rapid recognition of drug-resistance/sensitivity in
leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical
cluster analysis, Analyst, 138:3934-3945, 2013.
2. Bellisola G, Bolomini Vittori M, Cinque G, Dumas P, Fiorini Z, Laudanna C, Mirenda
M, Sandt C, Silvestri G, Tomasello L, Vezzalini M, Wehbe K, Sorio C. Unsupervised
explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells
mid-infrared spectra. Analyst, 140:4407-22, 2015.
3. Perrotti D, Silvestri G, Stramucci L. Chronic Myelogenous Leukemia (CML): Current
Research Focus. The Hematology Journal 9:91-102, 2015.
4. Laidlaw K., Berhan S., Liu S, Silvestri G, Holyoake T, Frank D, Aggarwal B.B., Perrotti D.,
Jørgensen H., Arbiser J. Cooperation of imipramine blue and tyrosine kinase blockade
demonstrates activity against chronic myeloid leukemia. Oncotarget, 7:51651, 2016.
5. Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in
Chronic Myeloid Leukemia: the leukemic stem, progenitor and stromal cell interplay. Current
drug targets, 18:377-388, 2017.

Submitted or In-Revision Peer-reviewed journal articles


1. Silvestri G., Stramucci L., Ellis J., Harb J., Neviani P., Eisfeld A.K., Zhang B., Srutova K.,
Gambacorti-Passerini C., Pineda G., Jamieson CHM., Calabretta B., Stagno F., Vigneri P.,
Nteliopoulos G., May P., Reid A., Garzon R., Roy D.C., Moutuou M.M., Guimond M.,
Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F.,
Marcucci G., Qi J., Machova-Polakova K., Zou Y., Fan X., Baer M. R., Trotta R. and Perrotti
D. The tumor suppressor miR-300 preserves cancer stem cells and inhibits NK cell anticancer
immunity. Nature, submitted, 2018.
2. Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P,
Sovova Z, Koblihova J, Stopka T, Perrotti D and Machova Polakova K. BCR-ABL1 mediated
miR-150 downregulation throught MYC contributed to myeloid differentiation block and
resistance in chronic myeloid leukemia. Haematologica, under revision, 2018.